Operator
Ladies and gentlemen, good day and welcome to the Aequitas Chemicals Limited Q3 FY26 earnings conference call hosted by JM Financial Institutional Securities Limited. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.
Should you need assistance during the conference call, please signal an operator by pressing star, then zero on your touchtone phone. Please note that this conference is being recorded.
I now hand the conference over to Mr. Krishan Parwani from JM Financial.
Thank you and over to you, sir.
Krishan Parwani
Good evening, everyone, and thank you for joining us on Aequitas Chemicals' Q3 FY26 earnings conference call. Today, we have with us Aequitas Chemicals' management represented by Mr.
Naresh Patel, Chairman and Managing Director; Mr. Abhishek Patel, Vice President Strategy; and Mr.
Bhavin Shah, Chief Financial Officer. I would now like to invite Mr.
Bhavin Shah to initiate the proceedings. Over to you, sir.
Thank you.
Bhavin Shah
Thank you, Krishan. Good evening, everyone.
We are pleased to welcome you all to our earnings conference call to discuss Q3 FY26 financials. Please note that a copy of our disclosure is available on the Investors section of our website as well as on the stock exchanges.
Please do note that anything said on this call which reflects our outlook towards the future or which could be construed as forward-looking statements must be viewed in conjunction with the risks that the company faces. The conference call is being recorded, and the transcript along with the audio of the same will be made available on the website of the company and exchanges.
Please also note that the audio of the conference call is the copyright material of Aequitas Chemicals and cannot be copied, rebroadcasted, or attributed in press or media without specific and written consent of the company. Now, I would like to hand over the floor to our Chairman and Managing Director, Mr.
Naresh Patel, for his opening statement. Over to you, sir.
Naresh Patel
Thank you, Bhavin. Good evening, everyone.
I hope you are all doing well. Wishing you and your family a very happy and prosperous New Year.
I will provide an overview of the strategic initiatives we are undertaking before handing over to Abhishek for detailed business updates. As Aequitas is evolving into a diversified chemicals company with multiple business verticals.
Allow me to walk you through each of them. Starting with our core business of pharmaceutical intermediates, our focus remained on sustaining the robust growth engine that we have built over the years.
Additionally, we are actively pursuing CMO and CDMO opportunities to accelerate growth in this segment. We have developed a strong pipeline with four products already validated, and we expect some of these opportunities to begin contributing to our top line from FY27 onwards.
Moving on the battery chemicals business, I'm delighted to share that we inaugurated a new block at our Jhagadia facility dedicated exclusively to battery chemicals on 19th January 2026. While Q4 will primarily be a quarter of trial production, testing, validation, and the commencement of the commercial operations, we expect this business to ramp up significantly from Q1 FY27.
Our third important vertical is semiconductor chemicals, where we are in the early stage of seeding business both in BFC and IndieChem, our South Korean joint venture, to new customer in South Korea, Japan, and Taiwan. We are witnessing encouraging traction from clients in both businesses.
At BFC, engagement with a Japanese customer has been very promising. In other than Haryas products, at IndieChem, we have already initiated discussions with various clients regarding our product offerings.
Overall, I believe that FY2028, these three business verticals will operate as independent, self-sustaining growth engines, each contributing meaningfully to our overall top line. Coming to our quarterly performance, I'm pleased to report that we continue our strong growth trajectory.
Revenue from operation came in just shy of ₹400 crore this quarter, which was accompanied by our highest ever margins, leading to our profit after tax for the quarter crossing the milestone of ₹100 crore mark. I will let Bhavin discuss financials in detail later.
To conclude, based on the strength of our current order book, we are revising our revenue guidance upward from 25% to around 30% growth for FY26. With that, I would like to hand over to our Vice President of Strategy, Abhishek Patel, who will walk you through the detailed business update.
Over to you, Abhishek.
Abhishek Patel
Thank you, Naresh. Good evening, everyone.
Let me take this opportunity to share further insights into our business performance for the quarter. Starting with advanced pharmaceutical intermediate segment, this segment delivered a robust performance with revenue of ₹351.1 crore in Q3 FY26, reflecting a strong year-on-year growth of 46.8%.
The growth was primarily driven by our CDMO business, complimented by steady contribution from our core advanced pharmaceutical intermediate segment. Moving on to the specialty chemical segment, revenue for this segment stood at ₹42.1 crore during this quarter, registering a strong year-on-year growth of 17.2%.
Our commodity chemical subsegment recorded consistent growth driven by high volume, stable pricing, which was supported by recovery in BFC business. Now turning to the capex, capex for nine-month period stood at ₹143 crore, primarily directed towards Jhagadia site for battery chemical project and pilot plant project at Sachin site.
Let me provide some additional updates on our key projects. Regarding electrolyte additive capex at Jhagadia, as Naresh mentioned, first phase of electrolyte block is inaugurated on 19th January 2026.
The second phase of capex is currently ongoing and is expected to be completed within next six months. Pilot plant capex is slightly delayed due to delay in equipment arrival.
It is now expected to be completed by Q1 FY27. Due to spillover of second phase of battery chemical capex as well as the pilot plant capex, total capex for the FY26 expected to be around ₹220 crore versus ₹250 crore which we guided in our previous call.
Apart from this, another major cash outlay during the year will be our investment in South Korea joint venture, IndieChem. Till now, we have invested close to ₹130 crore in this joint venture.
The total investment we announced for this venture was around ₹200 crore. We have sufficient cash on hand as well as strong cash flow generation to fund this cash outlay.
Now coming back to the business updates, starting with pharmaceutical intermediate segment, for ex-CDMO business, we have a couple of new products that have already started ramping up, and we believe they will continue drive the growth. For some of our top products, we have been able to deliver higher single-digit growth.
Now you might look at the numbers and observe that this business is not growing as strongly as it used to. This is because we have carefully taken strategic decision to review our product portfolio and let go low-margin products.
That's why you see now quality growth is coming. Coming to CDMO business, as Naresh mentioned, four products which have been validated in the current financial year should start contributing to the top line from FY27.
Additionally, we are expected to complete sampling and validation batches for some more products in coming quarters. This shows our CDMO pipeline continued to grow strongly, which will take us swiftly to our CDMO guidance of ₹1,000 crore by FY28.
On battery chemical side, we already have order in hand with good revenue visibility for FY27 for VC and FEC. As mentioned in earlier calls, we have added two more products to this business, and these products are expected to start contributing to top line from mid-FY27.
On semiconductor business side, Naresh covered most of the important update in his remarks. The only thing I would like to add is the capex for the IndieChem JV is progressing as per the plan.
Finally, on a note of corporate excellence, we are proud to share that our founder and CMD, Mr. Naresh Patel, has been recognized amongst the IDFC FIRST Private and Hurun India's Top 200 Self-made Entrepreneurs of the Millennium 2025.
This prestigious ranking celebrates the visionary behind the most valuable companies founded in India since 2000. For our stakeholders, this recognition is powerful validation of the entrepreneurial grit and the leadership that has shaped our company's trajectory.
As we continue to redefine our place in India's economic future, we remain committed to the same spirit of innovation and value creation that is our awarded honors. To conclude, as Naresh guided, we expect revenue from operation to grow by 30% in FY26.
We also upgrade our EBITDA margin guidance from 28% to 30% to 32% to 35% range for our full year. With that, I will now hand over our floor to Chief Financial Officer, Bhavin Shah, who will walk you through the financial update.
Over to you, Bhavin.
Bhavin Shah
Thank you, Abhishek. I would like to briefly highlight the key performance metrics for the quarter and nine months of FY26 before we open the floor for questions.
Let me start with the quarterly performance. Revenue from operations for the quarter reached ₹393.2 crore, representing 43% growth YoY.
Gross profit for the quarter was ₹224 crore, reflecting a 76.1% increase compared to the same period last year. The gross margin expanded by 1,073 basis points YoY to 57%.
Gross margin was driven by improved product mix. EBITDA for the quarter was ₹150.7 crore, which represent more than twofold increase compared to the EBITDA of the same period last year.
EBITDA margin was at 38.3%, up 1,335 basis points YoY. EBITDA margin was driven by expansion in gross margin as well as operating leverage.
PAT for the year, PAT for the quarter was ₹106.2 crore, up 133.7% YoY. PAT margin for the quarter was 27%, which show an expansion of 1,049 basis points YoY.
Moving on the nine-month FY26 performance, revenue from operations for the nine months for nine months of the year reached ₹906.6 crore, representing 29.8% increase year-over-year. EBITDA for the nine-month '26 was ₹296.9 crore, which was 2x compared to the same period last year.
PAT for nine-month FY26 was at ₹222.1 crore, which more than doubled compared to the same period last year. Moving on to the balance sheet items, net cash and cash equivalent were at ₹129.5 crore as on 31st December 2025.
Our working capital for the quarter improved to 111 days. This mainly on account of higher debtor days, whereas inventory and creditors remained stable.
With that, I request the moderator to open the floor for questions. Thank you.
Operator
Thank you. We will now begin the question and answer session.
Anyone who wishes to ask a question may press star and one on their touchtone telephone. If you wish to withdraw yourself from the question queue, you may press star and two.
Participants are requested to use handset while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles.
The first question comes from the line of Rikin Shah with Boring AMC. Please go ahead.
Rikin Shah
Hi, sir. Congratulations on a blockbuster performance.
First, I wanted to ask, the overall direction of the semiconductor chemicals, both the verticals. In the last call, we have mentioned about some new product launches and trial batches for BABA, and also if you can share, the same question, share some light on the guidance of the facility in Korea coming up.
Thanks.
Abhishek Patel
On BABA Finechem business side, as we discussed last time also, as our endeavor is to promote our products ex of Haryas business, which we were not marketing earlier at the time of acquisition, that we have started marketing in the newer geography and that has shown a very good results. You can see the BABA Finechem business has started turning around in terms of revenue.
I think the last quarter was more of a kind of bottom point for us from where we have started positively from this quarter onwards. Going forward, we are expecting some more traction coming in business.
It will be a slow process, but we are already on that good part of growth, it's an encouraging results for us. From IndieChem side, the capex has started almost four months back, and it is progressing well as per the plan.
We have already invested ₹130 crore towards the capex, and hopefully, by end of this calendar year, we should be able to complete the capex and start the business.
Rikin Shah
Got it, sir. All right.
Last quarter also, we had mentioned in non-CDMO business, and you also mentioned again, a change in the product mix. Also, you've mentioned there is some conversion to flow technology.
My question is that some of the legacy molecules, they could have been transferred to flow tech much, much earlier. What has essentially changed and why has this increased this much right now?
Just trying to reason with what is happening.
Abhishek Patel
When we talk about the changing to the flow chemistry and all those things, that is not related to the CDMO business. CDMO business is a completely with closed connection with the customer.
We cannot right away change to any of those things.
Rikin Shah
Right, sir. I meant the non-CDMO business only, sir.
Abhishek Patel
Yeah. For ex-CDMO business, this is a very standard process for us to look at every product on a monthly and a quarterly basis.
If there is any threat related to margin or any cost pressure, we do the cost improvement, margin improvement measure for this. This is how we keep on upgrading our products, working on our cost on a regular basis.
Those are the permanent kind of things which is the margin improvement. More of a margin improvement for this quarter is again because of the product mix only.
If you look at our gross or material margin level, it is an improvement of 1.2%, which is where you see the product mix shifting. Rest of the margin is coming from the operational efficiency.
Rikin Shah
Got it, sir. Sir, what utilization would we be in Ankleshwar?
Along the same line, sir, what is the plan for incremental pharma intermediate capex post Ankleshwar is at peak capacity utilization?
Abhishek Patel
At Ankleshwar plant, the utilization has been 40% 40% for the quarter. Slowly, because see, once the plant get ready, which was completed last quarter only, it's a time for products to get validated from the newer site, and slowly, it will start ramping up from that site.
Newer product which are coming into the basket from our product portfolio and R&D line, that now we are doing at the Ankleshwar site as well as some of the existing product which we are just slowly transferring to the newer site. In terms of capex for this site, it is still premature to announce anything.
As we mentioned, this largely covers our growth requirement till FY28. Before 1.5 years, we may come up with some capex plan based on the market condition and future growth requirement.
Rikin Shah
Got it, sir. You mean 40% for Block 3 or for the entire site?
Abhishek Patel
For entire site covering now the all blocks available time for availability of all block, whatever time it was.
Rikin Shah
Got it. Sir, and you have mentioned three new CDMO projects in H1 FY26, and you had also guided that they will ramp up in H2 FY26.
How has been the movement of these new CDMO projects ex of our core CDMO molecules?
Abhishek Patel
Ex of first CDMO, which you are talking about, four number of projects have already been validated. These are already commercial products, but meaningful revenue we are expecting from next financial year onward.
Meanwhile, there are many other products which are going for validation on a continuous basis, expected in this quarter also.
Rikin Shah
Got it, sir. Just a last question from my side in terms of sustainability of gross margins, what would be your outlook for that, for at least if you can't say for a few years, then maybe for FY27?
Abhishek Patel
Actually, we are not guiding for any of margin, but we can discuss at a relevant time for FY27.
Rikin Shah
All right, sir. Thank you so much.
Good luck.
Abhishek Patel
Thanks.
Operator
Thank you. The next question comes from the line of Sudarshan Padmanabhan with ASK.
Please go ahead.
Sudarshan Padmanabhan
Thank you for taking my question. Actually, taking forward from the previous participant, now two things.
One is we know that the oncology product itself is doing well, if we go by Innovent's commentary this year, and also there is a lot of product life-cycle extension happening. If I look at three years and talking about the ₹1,000 crore target, how is the contribution from non-oncology products going to be?
If you can give some color on the dependency of oncology and how are the other products in the pipeline?
Abhishek Patel
As we mentioned, we have already validated four more products, and during my commentary, I mentioned this gives us the confidence that we'll be able to cross ₹1,000 crore mark for the CDMO business by FY28. Apart from that already going oncology product, we have a very good pipeline of CDMO products in our product basket.
In fact, that has been very encouraging seeing at the kind of growth we are seeing for all those product development happening at R&D.
Sudarshan Padmanabhan
Sure. Sir, then coming to the electrolyte business, that is on the battery chemical side.
Now we are looking at vinyl carbonate and fluoroethylene carbonate, couple of products. If I take two, three years down the line, are we looking to expand this basket?
What is the strategy here in terms of going with the bouquet of products?
Abhishek Patel
Yes, of course. This has been two stepping stone kind of product for us through which we get into this business.
As we discussed last quarter also, we have already commercialized two more products in this space. Capex Phase 2 is already been announced, which is already under implementation and expected to get completed by Q1 FY27.
There are more products which are already under development and for which business development is also going on, for which you can find our list of product at our website also.
Sudarshan Padmanabhan
Sure. This will largely be towards the OEMs, right?
The battery cell OEMs.
Abhishek Patel
Yes.
Sudarshan Padmanabhan
Whom we have tied up with. Okay.
Sure. Thanks a lot, sir.
I'll join back the queue. All the best for the future.
Operator
Thank you. The next question comes from the line of Krishan Parwani with JM Financial.
Please go ahead.
Krishan Parwani
Yes, hi, sir. Congratulations once again on very strong results.
Just a couple of questions from my side. First, have you signed or are looking to sign any new CDMO contract for the four products that have been validated you mentioned?
Abhishek Patel
Yes, of course. Those are with the originators, and the relevant contract will be signed as relevant time.
Krishan Parwani
Okay. Would you be, let's say, I know you will not be giving out the names of the products, but would you be, let's say, signed the contract or no?
Abhishek Patel
Sorry, I didn't get you. Saying
Krishan Parwani
as and when you sign the contract, would you be announcing the same?
Abhishek Patel
We will update as and when some material update is to be provided as per the regulatory requirement.
Krishan Parwani
Sure, sir. Just one clarification, on IndieChem investment, you said ₹150 crore will be in FY26.
Basically, ₹370 crore cash outflow in FY26, correct? ₹220 crore the capex and ₹150 crore the investment.
Abhishek Patel
We have invested ₹140 crore by this year. With the completion of capex electrolyte, it should be ₹220
Krishan Parwani
crore.
Abhishek Patel
IndieChem investment is ₹130 crore for the full year.
Krishan Parwani
Okay. Basically, at ₹350 crore to ₹370 crore cash outflow in FY26, correct?
Abhishek Patel
Yes. Next round of investment for IndieChem, part may come in this quarter also.
Krishan Parwani
Okay. Noted.
Did you mention the battery chemicals incremental capex for the two new products that you have added?
Abhishek Patel
That is what the second phase is.
Krishan Parwani
Okay. Revenue contribution you said will begin in the mid of FY27 from these two new products?
Abhishek Patel
Yes.
Krishan Parwani
Okay. VC, FEC is already begun, I think Naresh mentioned, from 17th January or so?
Abhishek Patel
No, let me clarify on this. On 19th of January, plant inauguration was done.
Then now we are in the process for validation, trial batches, and then commercialization will happen, probably by end of this quarter.
Krishan Parwani
Understood. Basically, 1Q FY27 we can assume the contribution from VC and FEC.
Abhishek Patel
Yes. You rightly said, as you know that we have already order in place.
By quarter end, we should be able to, hopefully, start commercial supply.
Krishan Parwani
Perfect. Last bit, which cost overheads, let's say, contribute to reduction in other expenses this quarter?
Because other expenses declined quite a lot this quarter, just wanted to understand the reason there. It's only a ₹3 crore reduction, but yeah.
Naresh Patel
Krishan, it was largely on account of savings on energy cost. Then there are a few consumable and repairs item.
We have improved many of our internal processes. All things has helped us to reduce on other overheads for this quarter.
Krishan Parwani
Understood. The energy savings is from the solar plant that we had installed, correct?
Naresh Patel
Largely from that.
Krishan Parwani
Yeah. Okay.
Thank you so much for answering my questions. Wish you all the best.
Thank you.
Operator
Thank you. The next question comes from the line of Abhijit Akella with Kotak Securities.
Please go ahead.
Abhijit Akella
Yeah. Good evening.
Thank you so much for taking my questions. First on the battery chemicals piece, if you could please just remind me what the new capacity addition is from the two new products coming up by one one one each, I guess.
What is the capex that's being invested into those?
Abhishek Patel
Actually, we have not announced any capacity number for this capex. The capex plan is ₹40 crore.
Abhijit Akella
Okay. Got it.
With regard to BABA, given that the business has started to turn around, is there a revenue, sort of guidance that we could look at for FY26 as a whole?
Abhishek Patel
As of now, we have not given any guidance on this. Obviously, this is the season for budget also.
We may give the guidance at relevant time.
Abhijit Akella
All right. Just one last one from my side with regard to the product concentration, it does seem like maybe the top CDMO product is driving a lot of the growth for the company over the last year or so.
We have a lot of other growth projects coming up in the next year to two years. If we look out maybe three to five years, what sort of product concentration would you expect to see from the top product just over that timeframe?
How significantly can we de-risk ourselves from that concentration risk?
Abhishek Patel
As we already discussed, we are working and, as we mentioned, four products are already validated and many more products in pipeline for CDMO business apart from that traditional business. Then another growth engine of electrolyte and semiconductor is coming up.
Obviously, idea is to de-risk product concentration going forward, but I will not able to give you any guidance on the product mix in next three-year times.
Abhijit Akella
Got it. No, thank you so much.
Abhishek Patel
Generic side also, the products like apixaban, rivaroxaban are already progressing well. Those are also a kind of engine for apart from the CDMO space.
Abhijit Akella
Okay. Thank you so much.
All the best.
Operator
Thank you. The next question comes from the line of Pratik with Union Mutual Fund.
Please go ahead.
Pratik Dharmshi
Yeah. Many congratulations, Abhishek, Naresh, for a great set of numbers.
A couple of questions from my side. On your onco CDMO, how's outlook looking in terms of new indication, new geography additions?
What sort of outlook are you envisaging based on your interaction with the customers for the onco CDMO?
Abhishek Patel
See, for this business, as this is a CDMO business, we are completely driven by whatever projection has been given by our end customer. Obviously, as you read in the market and related to product and market expansion, but we are giving the ₹1,000 crore guidance based on whatever the customer expectation is there till FY28.
Pratik Dharmshi
Got it. In terms of this recent EU FTA, will we benefit in any ways?
Abhishek Patel
Let's say, for EU FTA deal, obviously, it will be a welcome deal for not only for us, it's for whole industry. We may also be the beneficiary of whole as a industry cycle.
Pratik Dharmshi
Are any of our products under tariffs?
Abhishek Patel
We are supplying on a product CIF based and it's a customer's requirement to get it custom clear at their end. For us, it has not been any time matter of concern earlier also.
Pratik Dharmshi
Got it. Yeah.
Thanks a lot and wish you all the best.
Abhishek Patel
Thanks.
Operator
Thank you. The next question comes from the line of Rohit Nagraj with 360 ONE Asset.
Please go ahead.
Rohit Nagraj
Thanks for the opportunity and congrats on very strong set of numbers. Sir, first question on CDMO front.
During the first nine months, how many total commercial products that we are servicing on the CDMO? What would be the mix between pharma and agro?
An allied question to that, when we see FY28 ₹1,000 crore, what is the kind of mix that we are looking at from pharma and agro? Thank you.
Abhishek Patel
No. When we talk about ₹1,000 crore revenue, it is for CDMO business only.
When we talk about, it's not about split between pharma and agro.
Rohit Nagraj
I'll rephrase that question. Rohit,
Bhavin Shah
there is no agro business in CDMO. All the CDMO is only from pharma.
Rest Abhishek will give answer.
Abhishek Patel
Okay. All CDMO business is to pharma only, no agro business is there.
In terms of product mix that we are not disclose anywhere because of the confidentiality nature of the CDMO contracts.
Rohit Nagraj
Sure. I'll just rephrase the question.
How many molecules are currently being commercialized? When we'll reach, say, ₹1,000 crore, what is the number of molecules that will be commercialized and those will be serviced?
Abhishek Patel
As on date, we have already five commercialized product, as we mentioned. Going forward, obviously, the number will be higher.
It is difficult to say the number of products which will be contributing at the end of FY28.
Rohit Nagraj
Sure. That's clear.
A second on the IndieChem venture. When do we expect the commercialization of the facility?
Probably the first year of operation and any visibility in terms of how the revenues are likely to be scaled up and what kind of arrangement in terms of product offtake that we are currently looking at? Thank you.
Abhishek Patel
For IndieChem project, as I mentioned, our plant should plant capex should completed by this calendar year, year 2026, and next year on calendar year onward, we should see a revenue coming up in this business. In terms of number or the size or a scale of this business, largely, you can expect that for the semiconductor business, the asset turn will be in the range of 1:1 and with a high EBITDA margin as compared to pharma business.
Rohit Nagraj
Sure. Just one clarification.
For the first nine months, what could be the CDMO contribution in our total revenues?
Abhishek Patel
That I'm afraid I will not be able to
Rohit Nagraj
disclose
Abhishek Patel
this number.
Rohit Nagraj
No worries. Thanks a lot for answering all the questions and all the best, sir.
Abhishek Patel
Thanks.
Operator
Thank you. The next question comes from the line of Jason Soans with IDBI Capital.
Please go ahead.
Jason Soans
Sir. Thank you so much for taking my question and really congratulations on a very strong set of numbers.
Sir, first question, just wanted to understand, of course, I understand that the CDMO piece is doing really well, but around two quarters back, you did give some color on how the CDMO piece is doing and the non-CDMO piece is doing. CDMO, yes, doing very well.
Just wanted some color on the non-CDMO business as well, how is it shaping up?
Abhishek Patel
Non-CDMO, as I mentioned during my commentary also, the non-CDMO pharma intermediate business is also growing in a higher single-digit number. You may feel like it's a lower number, but as I mentioned, now we are more focusing towards the quality growth as compared to the commodity intermediate products.
In terms of growth for this business, as I mentioned, some of the generic products, couple of generic products are already doing well in this financial year or in the last quarter also, and some of the new products are expected to join in this business for coming quarter also. These are the products which are driving growth for us in non-CDMO business also.
Because the pharma CDMO business is growing exponentially, it has become the more highlighting point for all of us.
Jason Soans
Yes. Sure, sir.
Sir, just you usually do give the EBITDA margins for the segments. Sir, just for the API business and for the specialty chemicals, what are the segmental EBITDA margins, sir, for this quarter?
Abhishek Patel
For the quarter, EBITDA margin for pharma business is around 41%, and specialty is around 12%.
Jason Soans
Okay. Sir, related to that, just wanted to understand, I know additives hasn't started yet, but it will soon start.
Just wanted to understand initially what kind of margin are you baking in for this additives business and first start, and then at optimum utilization, is a 20% margin safe to basically incorporate at an optimum utilization scale?
Abhishek Patel
See, we have not guided any margins expectation for this business as of now. What I can share is the margin profile will be below the traditional pharma intermediate business and above the existing paraben or commodity chemical business.
Obviously, at the beginning, the margin will be lower because of the operability or the scale of the business, but it will get better. As we have a good contract in hand, the scale-up should be much faster to get the operating efficiencies.
Jason Soans
Sure, sir. Sir, just to clarify, the capex for the electrolyte additives was ₹177 crore when you mentioned it.
Now you're adding ₹40 crore more to it. Is the understanding right?
Abhishek Patel
Yes.
Jason Soans
That's right. Okay.
That's good. So, ₹177 crore and ₹40 crore will be adding more.
Again, another clarification which I had is you said that the capex is ₹220 crore for '26. So, ₹220 crore plus your ₹130 crore going to IndieChem, that kind of totally becomes ₹350 crore.
Is that also understanding should be right, correct?
Abhishek Patel
No. For full year, for ₹220 crore in full will not get completed by March '26, but when it gets completed, total for electrolyte, total capex will be ₹220 crore.
For at a full company level, the total capex total capex will be ₹220 crore including what including all the segments.
Jason Soans
Okay. Even including the IndieChem investment, it will be ₹220 crore?
Abhishek Patel
I am talking about capex. It will be by end of the year, capex towards electrolyte will be in the range of ₹170 crore for this financial year, ₹20 crore maybe towards the pilot plant, and remaining will be maintenance and some portion of the solar capex, totaling to ₹220 crore.
Jason Soans
Okay. And ₹130 crore is over and above this, the IndieChem is separate from this, that's what you're saying?
Abhishek Patel
IndieChem investment is
Jason Soans
over and above this.
Abhishek Patel
Your question is right. ₹220
Jason Soans
crore
Abhishek Patel
plus ₹130 crore, overall layout will be around ₹350 crore. Yes.
Jason Soans
Yes, yes, yes. Sure.
Sure. Sir, just lastly wanted to understand, sir, I understand the BFC and IndieChem are basically focused on the semiconductor space.
Just, sir, if you could give us some understanding on some color on how complex, how margin high margin will this products be, probably you are saying '28 by '28 you'll see meaningful revenue from these set of businesses as well. If you could give us some color on how complex, how margin high high margin this products can be, or what potential these products can contribute?
Abhishek Patel
What I can share to you is you already know about the margin profile of BFC because it's already our existing business. You can refer our financials also.
On top of that, I can add that at IndieChem in South Korea, we are going for further value addition in this space. This what I can share to you on this.
Jason Soans
Sure, sir. Okay.
Thank you so much for answering my questions. Thank you.
Operator
Thank you. The next question comes from the line of Sajal Kapoor with Antifragile Thinking.
Please go ahead.
Sajal Kapoor
Hi. Thanks for the opportunity, and fantastic work, Aequitas team.
Moving, not just looking at this quarter, moving gross margins from 40%, 45% to upwards of 55% now in just about two years is a clear testament to your focus on efficiency and smart execution. Done on that.
Coming to my questions, three years from now, what would convince us that Aequitas successfully transitioned from a diversified specialty chemicals company to a sort of scientifically differentiated electronics grade chemicals platform? What would failure look like three years out?
Abhishek Patel
As our Chairman, Naresh, already mentioned during his speech, for him, in next three years, he expect all his three verticals not only standing on its own feet, they would be contributing meaningfully and generating a good amount of profit in all those segments. This is what we would like to see in next three years' time.
Sajal Kapoor
Right. In terms of some of the critical capabilities, be it talent, purity control, customer trust or capital, what out of these will be the hardest to scale and how are you positioning yourself just to protect the downside?
Naresh Patel
Okay. Sajal, when we started this journey, we design the plant and everything, all the timelines and requirement of the project is defined and accordingly, we are having successfully installation of the plant as well as parallelly recruitment of the people, talent, and also technology implementation.
Everything is as per the program and timeline, we are doing that. We don't see any hurdle in this kind of technical people available, or secondly thing is that whatever the processes are there, that is in-house designed.
We are a strong knowledge about our processes. Wherever we don't know the strongness of that, then we do a JV like an IndieChem, where we are doing an operation, but the knowledge is coming from our partner.
This is how we solve our problem or any issues which is coming in that. I hope this will help you to understand.
Sajal Kapoor
Yes, it does. Thank you.
Lastly, beyond absolute R&D head count, which I think is currently about 130 odd scientists, beyond the absolute head count, how has our effective scientific throughput changed over the last sort of 12 to 18 months? You can measure it in terms of projects per scientist, time to qualification, or successful tech transfers to manufacturing.
I'm just trying to understand the rate of change that has happened in the organization above and beyond the R&D head count, which we keep publishing over the last 12 to 18 months, because a lot of material change has happened on the gross margin, as I said, and I've seen many chemical companies struggle with the gross margin, 40%, 35% in that range. Clearly, we have broken out.
Something must have happened beyond the absolute numbers, right? If you can just give us some sort of a qualitative understanding.
Thank you.
Naresh Patel
As when I started this journey in public, you always say that we are a company which a chemistry-driven company, R&D-driven company. Our core strength is our R&D, and our team, core people are very well knowledgeable about chemistry, what chemistry we do, we are very expertise in that.
We have more than 680 molecules develop in our R&D. That will help us to understand chemistry.
USP of incremental margin is not only R&D, but every all the sectors, there are several parameters which is contributing to make the margin improvement, which is not only including the process improvement, but also energy, technology, operational efficiency, these are all utility. Everything is combinedly work on that and that's how we had improved our margin.
Also the product mix, layoff some products which are almost old age and no margins remain in that. These are all things which is cumulatively effort done by the team and accordingly, we improve our margin.
R&D point of view, our run rate of developing around 50 odd molecules annually and which is we are doing very well. Sooner or later, we go for the expansion of our R&D also, as and when we required, we will announce that as well.
Sajal Kapoor
Right, because I was coming to that. Currently, we are at 130, 140.
You expect that number to bump up over the next 12 months or so, right?
Naresh Patel
Yeah.
Sajal Kapoor
Yeah. Yeah.
Okay. No, understood.
Thank you so much for answering all my questions, and wish you guys the very best. Thank you.
Naresh Patel
Thank you.
Operator
The next question comes from the line of Bharat Shah, an individual investor. Please go ahead.
Bharat Shah
Naresh, I didn't have any question, but I just wanted to congratulate you and the team. From a small firm with patchy businesses to specialty and multiple products, plus much more on the anvil, from a kind of commodity businesses in API and intermediate to specialty and developing CDMO with semiconductor and battery chemical specialties, I think the firm has come a fantastic way, and all of that in a relatively short period of time.
Hearty congratulations to you and the team. This is a dramatic performance.
Naresh Patel
Thank you, Bharat. All blessings of you and all investors.
Thank you. Please keep us vigilant and more vigilant to work on projects that encourage us to perform more and more better way.
Thank you, Bharat, for keeping trust in us.
Bharat Shah
No, thank you. I've also seen that interaction with your team members is never about numbers, but about the business, and how well, for example, Abhishek invariably deals with all business-related issues and how things are progressing.
It is very heartening. Otherwise, many of these discussions end up being very mundane, but this has been a refreshing exchange of views while talking to your team.
Abhishek Patel
Thank you, Bharatbhai. Thank you, Bharat,
Naresh Patel
for admiring my team. I'm really happy to hear this kind of acknowledgment from a very veteran person like you from industry.
Thank you. Thank you very much, sir.
Bharat Shah
Thank you.
Operator
Thank you. The next question comes from the line of Vignesh Iyer with Sequent Investments.
Please go ahead.
Vignesh Iyer
Hello, sir. Congratulations on excellent set of numbers.
My first question is on working capital part of it. Wanted to understand what was our working capital days in quarter three, net working capital, if you could give us a split of that inventory, receivable, and payable, if possible.
Bhavin Shah
It is 111 days. Debtor stand at 100 days, inventory at 55 days, and payable is at 44 days.
Vignesh Iyer
Okay. I think the inventory days are a bit higher than usual.
Any specific reason for that, and will we see that the days go down in quarter four?
Bhavin Shah
Traditionally, we say that 110 days are the standard for many quarters, and what we try to always see that we should reduce and come it down to 100 days. But 110 days is a very standard period and comfortable for looking at our business.
55 days of inventory, I believe that is a good benchmark in the industry also. So, 55 days is a comfortable standard for working with our kind of business.
Abhishek Patel
In fact, obviously there will be a many scope for improvement for inventory or working capital days. In fact, if you see, we have not only gone beyond our growth for the revenue, we have always kept our eyes on the balance sheet item and a cash flow.
If you see in last three years also, we have always sequentially improved our working capital days. Obviously, there will be a room for the improvement of inventory days or debtor days anytime.
We have always been a good cash flow-generating company if you see last three years' performance.
Vignesh Iyer
Definitely, definitely. Sir, that's all from my side.
Thank you.
Operator
The next question comes from the line of Vivek Gautam with GS Investments. Please go ahead.
Vivek Gautam
Sir, congratulations on a consistently good set of numbers. Sir, my question is about the opportunity size for our different segments, and number two is about the Chinese competition threat in any of the segments, sir.
Abhishek Patel
For Chinese competition, see, we are into the business of chemical and intermediate, we cannot ignore this Chinese competition, and we have been dealing with all those competition for almost more than a decade. What I can say is that we are very good at a chemistry, that is our strength, and we do multiple chemistry for any of the product at a large scale, which is a key or USP for us as against any Chinese competition.
That's the reason you can see that for majority of our top products, we are the leader covering more than 70%, 80% of the market share. It's nothing or something which we are dealing day in, day out.
In terms of market opportunity, let's say, for some of the products like anti-cancer, which is already going well, you can refer some of the presentation of our customer and end customers, which can give you the insight about these things. In terms of this product like electrolyte additive space, wherein VC and FEC, we have a very humble capacity of 2,000 metric ton as against the total VC and FEC market.
As of now, we are very small as against the opportunity size available both for the VC, FEC kind of electrolyte additive products as well as the semiconductor space, where we have only just started in this business. So, 2,000 metric ton for VC and 2,000 for FEC, it's a very small size as of now as against the full opportunity size.
Vivek Gautam
Sir, lastly, how much is the exposure we are having for the US market, and any impact of tariff and other things?
Abhishek Patel
We have very small amount of direct export to the US market, largely it is from our subsidiary called BABA Finechem only. We do not have much of the impact for US tariff.
Vivek Gautam
Thank you, sir. Keep up the good work, sir.
Operator
Thank you. The next question comes from the line of Akshay with AK Investments.
Please go ahead.
Akshay Kaila
Hello. Thank you for giving me this opportunity.
Congratulations on very strong set of numbers. Sir, all my questions has been answered, but my only question is that after FY26, can we grow sustainably by 25% to 30% year-on-year till next four to five years for a consolidated business?
Abhishek Patel
Sir, we have been growing for more than 25% not for last two, three years, we have grown more than 25% for more than decades. That is what we have already guided the market that for next three years also, we would be growing more than 25% at a revenue level.
Akshay Kaila
Yeah. That's right and very promising.
All the best for the future. Thank you so much.
Abhishek Patel
Thanks.
Operator
Thank you. The next question comes from the line of Jason Soans with IDBI Capital.
Please go ahead.
Jason Soans
Sir, thanks for taking my question again. Just a small question I had.
You have a 2,000-ton capacity of VC and FEC both, right? 4,000 in total, correct?
Yes. Sir, with the contract in place, any capacity utilization you are looking at going ahead?
With the contract in place, how much of that capacity of the 4,000 it would take?
Abhishek Patel
Because of confidentiality of the agreement, we will not be able to share the utilization. Otherwise, people will figure out the contract details.
We are not disclosing it. As I mentioned, we have good visibility in terms of contract for FY27 and going forward also, and we are expecting fast scaling up of this business.
Jason Soans
Okay. Okay.
Sir, just also, with all that happening in China with the anti-involution and things, and with lithium prices, electrolyte prices, and additive prices also going up, with lithium carbonate and all, do you think whatever you're seeing that bodes very positively for the additives business going ahead?
Abhishek Patel
For additive business, as I mentioned, we have already signed contract in place, which is more of a fixed pricing contract with variability if is there in terms of key raw material as well as the currency pricing. We believe in long-term supply or long-term relationship with the customers, and obviously, we earn our margin based on those already signed contract.
Jason Soans
Okay. Okay.
This contract is in place, probably for future contracts it would be beneficial, correct?
Abhishek Patel
As I mentioned, we believe not on the short-term gaining of this market movement, we more driven by the long-term supply contract.
Jason Soans
Okay. Sure.
Sure. That's all from my side.
Thanks. Thanks for answering my questions.
Operator
Thank you. The next question comes from the line of Chandra Rampuria with Arya Finvest.
Please go ahead.
Chandra Rampuria
Hello. Can you hear me, please?
Abhishek Patel
Yes.
Operator
Yes, sir. Please go ahead.
Chandra Rampuria
Yeah. Yeah.
Thank you, Naresh. Superb results and very well done.
I've been following your growth for some time now and really impressed. A short while ago, you mentioned in the context of the anti-cancer CDMO that the projections from the customer are in place till '28.
Just wanted to get the clarification, is it the projections are there till '28 or is the contract till '28? Look,
Naresh Patel
we never say that up to '28, we have some projection or something like that. We always say that we have a long-term supply contract for this anti-cancer.
Chandra Rampuria
Because a short while ago, you mentioned about the revenue guidance till '28 and that is based on customer projections, so that's why just this clarification.
Naresh Patel
No, no. The '28, we announce ₹1,000 crore CDMO business.
That CDMO business is not only belongs to anti-cancer, this will cumulatively of several other CDMO as well. We will be complete by 2028.
We reach to this milestone. This is what I said.
That milestone, ₹1,000 crore, is not belongs to the CDMO of anti-cancer, but this is a bundle of several CDMO business.
Chandra Rampuria
Oh, that's fine. That's fine.
Naresh Patel
I hope this will clarify your doubt.
Chandra Rampuria
Sure. Sure.
Sure. That's helpful.
Thank you.
Operator
Thank you. Ladies and gentlemen, due to time constraint, this was the last question for today.
I now hand the conference over to the management for closing comments.
Naresh Patel
Thank you to the JM Financial team for hosting our conference call. We appreciate everyone's questions and hope we have addressed most of your queries.
If we missed any of your questions, please reach out to our investor relations team, and we will get back to you promptly. Once again, thank you very much, and have a good evening.
Operator
Thank you. On behalf of JM Financial, that concludes this conference.
Thank you for joining us, and you may now disconnect your lines. Thank you.
Already premium?